Welcome to our dedicated page for BiomX news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.
BiomX Inc. (NYSE American: PHGE) is a pioneering clinical-stage microbiome and drug discovery company based in Israel. The company specializes in the development of natural and engineered phage therapies designed to target and destroy harmful bacteria associated with chronic diseases such as inflammatory bowel disease (IBD), colorectal cancer, primary sclerosing cholangitis, and chronic pulmonary infections in cystic fibrosis (CF) patients.
Utilizing advanced computational and synthetic biology research from globally renowned institutions, including the Weizmann Institute of Science and the Massachusetts Institute of Technology (MIT), BiomX's platforms discover and validate proprietary bacterial targets. Their flagship product candidate, BX004, aims to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients. This program has shown promising clinical results, achieving positive outcomes in both safety and efficacy in Part 2 of a Phase 1b/2a trial, with results expected to be published in November 2023. BX004 has been granted Fast Track designation by the FDA.
In addition to its CF program, BiomX has expanded its pipeline through a recent merger with Adaptive Phage Therapeutics (APT), adding BX211, a personalized phage treatment for diabetic foot osteomyelitis (DFO) caused by Staphylococcus aureus. This merger has bolstered BiomX's capabilities and financial resources, enabling the company to advance its clinical pipeline effectively.
BiomX enjoys strong backing from notable investors such as OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation, Takeda Ventures, Seventure Partners, Mirae Asset Global Investments, and SBI.
For more details on BiomX's ongoing projects and latest developments, visit www.biomx.com.
BiomX announced stockholder approval to convert its Series X Non-Voting Convertible Preferred Stock into common stock. The Series X Preferred Stock was issued during BiomX's acquisition of Adaptive Phage Therapeutics in March 2024 and a $50 million financing. The conversion will see up to 256,887,000 shares of common stock added to the outstanding share count. This move aims to help BiomX comply with NYSE American's listing requirement for $2 million in stockholders' equity, a condition they had previously failed to meet. The reclassification of proceeds from the Financing as stockholders' equity could help achieve compliance. BiomX's CEO highlighted the acquisition and financing milestones as important for BiomX's future growth, particularly with two Phase 2 clinical candidates expected to report significant results next year.
BiomX received a notice of non-compliance from NYSE American on May 23, 2024, due to failing to meet stockholders' equity requirements. The company has a capital deficiency of $9.54 million and reported losses for the past five fiscal years. The notice does not immediately affect the trading of BiomX shares, which will continue under the symbol 'PHGE' with a '.BC' designation for below compliance. BiomX must submit a compliance plan by June 22, 2024, and gain compliance by November 23, 2025, to avoid delisting. The company expects to resolve the equity issue by converting preferred stock to common stock, pending shareholder approval in July 2024.
BiomX (NYSE American: PHGE), a clinical-stage firm developing phage therapies, will present data from its Phase 1b/2a trial of BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. These findings will be shared at the 47th European Cystic Fibrosis Conference (June 5-8, 2024, Glasgow) and ASM Microbe 2024 (June 13-17, 2024, Atlanta). Key presentations include an oral session and ePoster at the European conference, and a Rapid Fire session and poster at ASM Microbe. The presentations will be accessible on BiomX's website on June 6 and June 17, respectively.
BiomX, a clinical-stage company advancing phage therapies, has reported its Q1 2024 financial results and provided updates on its programs.
Following its merger with Adaptive Phage Therapeutics in March 2024 and a $50 million private placement, BiomX has a cash balance of $44.1 million, providing a runway through Q4 2025.
Key clinical programs include BX211 for diabetic foot osteomyelitis, expecting Phase 2 results in Q1 2025, and BX004 for cystic fibrosis, with Phase 2b results anticipated in Q3 2025. Financially, net loss increased to $17.3 million, primarily due to changes in warrant values and merger-related expenses.
R&D expenses decreased to $4.1 million while G&A expenses rose to $2.7 million.
BiomX (NYSE American: PHGE), a clinical-stage company specializing in phage therapies targeting pathogenic bacteria, announced a conference call and webcast scheduled for May 21, 2024, at 8:00 a.m. ET.
The event will cover the company's first quarter 2024 financial results along with business and program updates. Participants can join the call via dedicated U.S. and international dial-in numbers, and the webcast will be accessible in the Investors section of BiomX's website.
FAQ
What does BiomX Inc. specialize in?
What is BX004?
Who are BiomX's research partners?
What recent merger did BiomX complete?
Who are some of BiomX's investors?
What are some of BiomX's current projects?
Where is BiomX Inc. based?
What technological platforms does BiomX use?
When can we expect results for BX004 Phase 1b/2a trial?
How can I get more information about BiomX?
